Distinct early serological signatures track with #SARS-CoV-2 survival - ScienceDirect
▻https://www.sciencedirect.com/science/article/pii/S1074761320303277
Dans cette étude les anticorps du plasma des sujets guéris (dirigés contre la protéine S ou spike) sont différents de ceux des sujets décédés (dirigés contre la protéine N ou nucléocapside).
Cette constatation pourrait se révéler utile pour évaluer l’efficacité des #vaccins.
▻https://www.eurekalert.org/pub_releases/2020-08/mgh-pph080620.php
“Most vaccine candidates in development are designed to elicit antibodies against spike antigen, which is the response we observed with individuals who survived natural infection,” Chu said. The N protein is produced at significantly higher levels in the virus than the S protein is, but previous studies have shown that an immune response to the N protein does not provide protection against coronaviruses related to SARS-CoV-2.